Weekly Analysts’ Ratings Changes for IDEXX Laboratories (IDXX)

IDEXX Laboratories (NASDAQ: IDXX) recently received a number of ratings updates from brokerages and research firms:

  • 2/9/2018 – IDEXX Laboratories was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 2/5/2018 – IDEXX Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $214.00 price target on the stock. According to Zacks, “IDEXX exited the fourth quarter on a solid note. The company continues to demonstrate solid growth globally on consistent consumable revenue gains. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently commercially launched Catalyst SDMA Test in North America. Solid organic revenue growth along with a raised guidance for 2018 buoys optimism. Moreover, over the past year, IDEXX has been trading above the broader industry. However, its high dependence on third-party distributors and intense competition continue to pose threats. The stock’s overvaluation is also a concern.”
  • 2/2/2018 – IDEXX Laboratories had its price target raised by analysts at Bank of America Corp from $200.00 to $220.00. They now have a “buy” rating on the stock.
  • 2/1/2018 – IDEXX Laboratories had its price target raised by analysts at Piper Jaffray Companies to $211.00. They now have an “overweight” rating on the stock.
  • 1/31/2018 – IDEXX Laboratories was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 1/31/2018 – IDEXX Laboratories was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “IDEXX continues to demonstrate solid growth globally on strong international expansion. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX widened its cloud technology portfolio by adding rVetLink.  Solid organic revenue growth along with a raised guidance for 2017 buoy optimism. Accordingly, over the past year IDEXX has been trading above the broader industry.  On the flip side, high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation is also a concern.”
  • 1/29/2018 – IDEXX Laboratories had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $210.00 price target on the stock.
  • 1/16/2018 – IDEXX Laboratories was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/16/2018 – IDEXX Laboratories is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $200.00 price target on the stock.
  • 1/5/2018 – IDEXX Laboratories was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/16/2017 – IDEXX Laboratories was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

IDEXX Laboratories, Inc. (NASDAQ IDXX) traded up $3.67 during trading on Monday, reaching $172.95. 726,100 shares of the company were exchanged, compared to its average volume of 590,727. IDEXX Laboratories, Inc. has a 1 year low of $140.63 and a 1 year high of $198.73. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of -11.26. The firm has a market cap of $15,084.48, a price-to-earnings ratio of 58.83, a price-to-earnings-growth ratio of 2.13 and a beta of 0.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The firm had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. During the same quarter last year, the business posted $0.58 EPS. The company’s revenue was up 14.2% on a year-over-year basis. equities analysts expect that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.

In other IDEXX Laboratories news, VP Brian P. Mckeon sold 6,602 shares of IDEXX Laboratories stock in a transaction on Monday, February 5th. The shares were sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the completion of the sale, the vice president now owns 47,040 shares of the company’s stock, valued at approximately $8,531,174.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce L. Claflin bought 1,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were bought at an average cost of $179.58 per share, with a total value of $179,580.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $179,580. The disclosure for this purchase can be found here. Insiders sold a total of 122,762 shares of company stock valued at $20,637,764 in the last ninety days. Company insiders own 2.77% of the company’s stock.

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Receive News & Ratings for IDEXX Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply